Latest Information Update: 07 Jan 1998
At a glance
- Originator SyntheMed
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Alopecia
Most Recent Events
- 07 Jan 1998 Discontinued-III for Alopecia in Netherlands (Topical)
- 07 Jan 1998 Discontinued-III for Alopecia in Belgium (Topical)
- 06 Jan 1997 Phase-III clinical trials for Alopecia in Netherlands (Topical)